Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
AI, alanine, alkaline, ALT, altogether, aluminum, aminotransferase, anemia, AppTec, arbitrarily, archived, artificial, aspartate, Assent, AST, asthenia, avoid, bill, BIOSECURE, blood, boost, brand, broaden, Canadian, capriciously, certiorari, China, Chinese, cohort, contravention, core, correct, Council, count, cytotoxic, deferral, dehydrogenase, destined, diarrhea, director, disaggregated, elevation, environment, ethical, Extortion, fashion, FDCA, firm, fixed, formulary, fresh, fulfilled, fulfillment, fundamentally, gathering, genomic, guide, headache, hemorrhage, highest, House, HTA, hybrid, image, Inferior, innate, Inspector, intelligence, interchangeable, intervene, intrusion, inventory, investor, licensure, lieu, media, military, mutation, nausea, navigate, network, neuropathy, neutropenia, nonclinical, Notwithstanding, ocular, onsite, outset, overseen, Parliament, pediatric, peripheral, petition, phishing, PIE, plaintiff, platelet, PMA, portal, PPACA, PREA, preparatory, prosecutorial, proteinuria, qui, reliable, remotely, renegotiated, reply, retaliatory, retroactive, retrospectively, reveal, reverse, Royal, Senate, shipment, simultaneously, social, steel, streamlining, subpopulation, supplement, tam, tension, thrombocytopenia, timeframe, tissue, today, Topic, unacceptable, unaffected, unlock, unstable, unverified, upifitimab, Vice, vitro, waiver, whistleblower, Windsor, wound, writ, WuXi
Removed:
AbbVie, abdominal, accounted, adapt, antibody, beneficiary, Biopharma, body, Bolt, Brazil, call, chain, chill, Colorado, complied, component, congruence, conjugating, consistency, constrain, continual, CRO, CTA, CTR, Daiichi, departure, derive, distinct, enabling, engendered, engine, evolved, existed, feature, formally, Genentech, Gilead, GMP, handle, herewith, hired, HMR, ImmunoGen, impairment, inseverable, Institute, judgement, jurisdictional, justification, learning, left, letter, line, Ludwig, Maine, manager, Mexico, mission, MRKDG, multicenter, nominate, nominated, pain, par, pertuzumab, Pfizer, Pharma, plc, project, proportion, protracted, ratably, ratio, receivable, Recepta, referendum, regime, removing, renal, resuming, resurgence, Roche, ruled, Russian, Sankyo, Seagen, shipping, SI, Takeda, trastuzumab, undergone, undermined, Vermont, virtually, withdrawn
Filing tables
Filing exhibits
Related press release
Associated MRSN transcripts
MRSN similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT
TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Mersana Therapeutics, Inc. (the “Company”) for the quarter ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the company, hereby certifies, pursuant to Section 1350 of Chapter 63 of Title 18, United States Code, that to the best of his knowledge:
1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: May 9, 2024 | /s/ Martin Huber | ||||
Martin Huber, M.D. | |||||
President and Chief Executive Officer (Principal Executive Officer) |
Dated: May 9, 2024 | /s/ Brian DeSchuytner | ||||
Brian DeSchuytner | |||||
SVP, Chief Operating Officer and Chief Financial Officer (Principal Financial Officer) |